Australija - engleski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 341.71 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 341.71 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 227.81 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 227.81 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Kanada - engleski - Health Canada

mylan pharmaceuticals ulc - atazanavir (atazanavir sulfate) - capsule - 200mg - atazanavir (atazanavir sulfate) 200mg - hiv protease inhibitors

Kanada - engleski - Health Canada

mylan pharmaceuticals ulc - atazanavir (atazanavir sulfate) - capsule - 300mg - atazanavir (atazanavir sulfate) 300mg - hiv protease inhibitors

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

avera mckennan hospital - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - reyataz® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if reyataz is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg) - atazanavir 300 mg - evotaz® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in the following populations [see dosage and administration (2.2, 2.3)] : use of evotaz in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see clinical pharmacology (12.4) ] . the concomitant use of evotaz and the following drugs in table 1, are contraindicated due to the potential for serious and/or life-threatening events or loss of therapeutic effect [see warnings and precautions (5.8, 5.9), drug interactions (7), and clinical pharmacology (12.3)]. evotaz is contraindicated: table 1: drugs contraindicated with evotaz alpha 1-adrenoreceptor antagonist alfuzosin antianginal ranolazine antiarrhythmics dronedarone anticonvulsants carbamazepine, phenobarbital, phenytoin antigout colchicine (when used in patients with hepatic and/or renal impairment) antimycobacterials rifampin antineoplastics irino

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

avera mckennan hospital - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 200 mg - reyataz® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if reyataz is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

a-s medication solutions - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg) - atazanavir 300 mg - evotaz® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults. limitations of use: evotaz is contraindicated: table 1 displays drugs that are contraindicated with evotaz. alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antianginal ranolazine potential for serious and/or life-threatening reactions. antiarrhythmics dronedarone potential for increased dronedarone concentrations. anticonvulsants carbamazepine, phenobarbital, phenytoin potential for decreased atazanavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance. antigout colchicine contraindicated in patients with renal and/or hepatic impairment due to the potential for serious and/or life-threatening reactions. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeut